SCM
BIIB icon

Steadfast Capital Management’s Biogen BIIB Stock Holding History

Steadfast Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-173,985
Closed -$53.3M – 61
2015
Q4 		$53.3M Sell
173,985
-778,877
-82% -$224M 1.02% 31
2015
Q3 		$278M Buy
+952,862
New +$315M 5.57% 3

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Steadfast Capital Management's BIIB Position: Q1 2016 in Review

Steadfast Capital Management sold out of Biogen (BIIB) in Q1 2016, closing a stake of 173,985 shares — an estimated $53.3M sold.

Steadfast Capital Management first reported a position in BIIB in Q3 2015 and held it in 2 quarters. The position peaked at $278M in Q3 2015. 948 funds tracked by Wall St. Rank hold BIIB as of Q1 2016.

  • Steadfast Capital Management reported no remaining Biogen position as of Q1 2016 after selling out during the quarter.
  • Steadfast Capital Management sold 173,985 Biogen shares in Q1 2016, an estimated $53.3M.
  • Steadfast Capital Management first reported a position in Biogen in Q3 2015 and held it in 2 quarters.
  • Steadfast Capital Management's Biogen position peaked at $278M in Q3 2015.
  • 948 funds tracked by Wall St. Rank held Biogen as of Q1 2016.

Based on Steadfast Capital Management's 13F filing for Q1 2016, filed 16 May 2016.